TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataKi: 440nMAssay Description:Irreversible inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 5 mins followed by substrate addition and measured...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataKi: 3.06E+3nMAssay Description:Irreversible inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 5 mins followed by substrate addition and measured...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataKi: 3.90E+3nMAssay Description:Irreversible inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 5 mins followed by substrate addition and measured...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human recombinant RET expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human recombinant RET expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human recombinant FLT3 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human recombinant FLT3 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 33nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 44nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 67nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 82nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 89nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Inhibition of N-terminal GST-tagged MNK2 kinase domain (72 to 385 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of N-terminal GST-tagged MNK1 kinase domain (37 to 341 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetBreakpoint cluster region protein/Tyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 210nMAssay Description:Inhibition of BCR fused full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) expressed in baculovirus expression system using...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ABL1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 240nMAssay Description:Inhibition of full length human recombinant N-terminal His-tagged ABL (2 to 1130 residues) T315I mutant expressed in baculovirus expression system us...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 260nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 272nMAssay Description:Inhibition of human recombinant FGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATPMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor UFO(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of Axl (unknown origin) using 5'FAM labeled KKKKEEIYFFF-NH2 peptide as substrate incubated for 1.5 hrsMore data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 350nMAssay Description:Inhibition of N-terminal GST-tagged MNK1 kinase domain (37 to 341 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Experimental Therapeutics Centre
Curated by ChEMBL
Experimental Therapeutics Centre
Curated by ChEMBL
Affinity DataIC50: 350nMAssay Description:Inhibition of N-terminal GST-tagged MNK1 kinase domain (37 to 341 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells using JH3 ...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 360nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase SMYD3(Homo sapiens (Human))
Experimental Drug Development Centre
Curated by ChEMBL
Experimental Drug Development Centre
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:Inhibition of SMYD3 (unknown origin) using MAP3K2 peptide as substrate pretreated for 30 mins followed by substrate addition and measured after 30 mi...More data for this Ligand-Target Pair